Is now the time to buy Sigma Healthcare?

Every now and then, the market gives investors a second chance at a story that's been hiding in plain sight. Sigma Healthcare (ASX: SIG) is one of them.

Long seen as a traditional pharmacy wholesaler, Sigma has quietly transformed into one of the most exciting healthcare growth stories on the ASX, and investors are only just starting to catch on.

After years of underperformance and restructuring, Sigma's merger with Chemist Warehouse has completely changed the game.

The deal brings together Australia's largest pharmacy brand and one of the country's biggest distributors, creating a vertically integrated powerhouse with enormous scale, pricing leverage and growth optionality.

It's the kind of structural shift that doesn't come around often.

Why Sigma is suddenly a growth story

Sigma's turnaround is being driven by three powerful forces: scale, efficiency and growth leverage.

1. Scale and reach

The Chemist Warehouse merger makes Sigma one of the largest players in the entire healthcare retail ecosystem.

The combined business services thousands of pharmacies, owns and operates hundreds of stores and moves billions of dollars' worth of medicines and products through its distribution network each year.

That kind of scale gives it real bargaining power with suppliers and meaningful cost advantages over smaller peers.

For years, Sigma operated largely behind the scenes - distributing to independent pharmacies, while Chemist Warehouse became a retail juggernaut. Now, as one integrated group, it has both ends of the value chain under one roof.

The result is better control over margins, supply security and pricing power, with the opportunity to capture value at every stage of the customer journey.

2. Synergies and margin uplift

Management expects annual cost synergies of around $100 million, mainly through logistics optimisation and procurement savings. That's significant for a business of this size.

More importantly, those savings can flow straight into higher margins or reinvestment for future growth.

Chemist Warehouse brings unmatched retail execution, while Sigma contributes the distribution backbone and long-standing relationships with regulators, manufacturers and healthcare professionals. Together, the combined business can unlock operating efficiencies across everything from warehouse automation to product sourcing. With the heavy lifting on

infrastructure now done, incremental growth should come at a much higher return on capital - exactly what long-term investors look for.

3. Structural growth and defensive earnings

Pharmacy and healthcare retail spending tends to be steady through the economic cycle - people don't stop buying medicines when interest rates rise. That gives Sigma a strong defensive base.

But what's exciting is the upside potential from Chemist Warehouse's aggressive store rollout plans, private-label expansion and entry into new wellness and beauty categories.

Private-label products in particular represent a major growth opportunity. They carry higher margins and stronger brand loyalty, while offering value to consumers.

Combined with the continued migration of health spending from hospitals to community retail, Sigma is exceptionally well positioned to capture share of wallet as Australians seek more affordable and accessible care options.

The numbers tell the story

Analysts are now forecasting double-digit earnings growth for Sigma over the next few years.

According to market estimates, Sigma's revenue is expected to grow at around 14% per annum, with earnings growth closer to 16%.

Those numbers reflect not only cost synergies but also genuine top-line momentum as Chemist Warehouse continues to expand domestically and potentially offshore.

The growth runway is long. Australia's ageing population, the rise of preventive health and wellness spending, and the shift to value-focused retailing all support Sigma's multi-year expansion story.

Few other ASX mid-caps offer such clear structural tailwinds combined with proven brand equity.

Valuation and why now

At around 18 times forward earnings, Sigma still trades at a discount to other high-quality healthcare names like Pro Medicus, despite a much faster near-term growth outlook.

The market has yet to fully price in the upside from synergy delivery, improved working capital and Chemist Warehouse's store rollout pipeline.

As integration progresses and earnings start to exceed expectations, sentiment is likely to follow.

Historically, when large-scale integrations in defensive sectors deliver on synergy targets, rerating happens quickly. Investors don't stay asleep for long.

This is also the right part of the market cycle for a business like Sigma. In a slower-growth economy where consumers are tightening spending, companies that offer value, resilience and earnings visibility tend to outperform.

Sigma fits that profile perfectly. It combines the everyday necessity of healthcare with the brand power and cost leadership of one of Australia's most recognisable retailers.

The bigger picture

The merger marks the start of a new era for Sigma, one that goes well beyond pharmacy distribution.

With Chemist Warehouse under its umbrella, Sigma now has access to real-time consumer insights, loyalty programs and digital channels that can drive higher-margin sales growth.

We're also seeing early signs of expansion into adjacent categories, vitamins, beauty, personal care and health technology - areas where Chemist Warehouse has already proven its ability to execute.

For investors, this translates to multiple growth levers: organic store growth, new product categories and potential international expansion as the Chemist Warehouse model is replicated overseas.

Bottom line

Sigma Healthcare today looks nothing like the Sigma of old.

The Chemist Warehouse merger has transformed the company from a low-growth distributor into a vertically integrated healthcare powerhouse with meaningful synergy potential, strong balance sheet support and a clear pathway to double-digit earnings growth.

In a market starved of quality growth names that can perform through the cycle, Sigma ticks many boxes.

It's defensive yet expanding, capital-light yet cash-generative, and led by a management team that understands both wholesale discipline and retail execution.

For investors willing to look beyond the short-term noise, Sigma offers the kind of growth story that still trades at a reasonable price, and that combination, in today's market, is hard to find.

My take, Sigma Healthcare (ASX: SIG) is a buy for investors looking for structural growth, steady compounding and exposure to one of Australia's most resilient sectors.

Get stories like this in our newsletters.